Tapinarof acts as an aryl hydrocarbon receptor (AhR) agonist. By selectively activatng AhR, a ligand-activated transcription factor expressed in skin cells, tapinarof modulates gene expression involved in skin barrier function, inflammation, and oxidative stress. This mechanism contributes to its anti-inflammatory and immune regulating properties, making it effective in treating chronic skin disorders such as plaque psoriasis and atopic dermatitis. Unlike traditional immunosuppressants or corticosteroids, tapinarof offers a non-steroidal approach, potentially reducing long-term safety concerns while delivering durable therapeutic benefits.